{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:00:11Z","timestamp":1792807211574,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s13555-025-01602-z","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T09:19:23Z","timestamp":1764062363000},"page":"535-547","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Use of Ruxolitinib Cream Results in Economic Benefits Compared with Dupilumab in Treatment of Patients with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy"],"prefix":"10.1007","volume":"16","author":[{"given":"Omar","family":"Noor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6042-5476","authenticated-orcid":false,"given":"Jinan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sturm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haobo","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilan","family":"Paranagama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelma C.","family":"Chiesa Fuxench","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Chovatiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"issue":"3","key":"1602_CR1","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jid.2018.08.028","volume":"139","author":"ZC Chiesa Fuxench","year":"2019","unstructured":"Chiesa Fuxench ZC, Block JK, Boguniewicz M, Boyle J, Fonacier L, Gelfand JM, et al. Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019;139(3):583\u201390. https:\/\/doi.org\/10.1016\/j.jid.2018.08.028.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"1602_CR2","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.jaci.2013.08.031","volume":"132","author":"JI Silverberg","year":"2013","unstructured":"Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013;132(5):1132\u20138. https:\/\/doi.org\/10.1016\/j.jaci.2013.08.031.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1602_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/DER.0000000000000034","volume":"25","author":"JI Silverberg","year":"2014","unstructured":"Silverberg JI, Simpson EL. Associations of childhood eczema severity: a US population-based study. Dermatitis. 2014;25(3):107\u201314.","journal-title":"Dermatitis"},{"issue":"4S","key":"1602_CR4","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/j.jaci.2017.01.009","volume":"139","author":"LF Eichenfield","year":"2017","unstructured":"Eichenfield LF, Ahluwalia J, Waldman A, Borok J, Udkoff J, Boguniewicz M. Current guidelines for the evaluation and management of atopic dermatitis: a comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology guidelines. J Allergy Clin Immunol. 2017;139(4S):S49\u201357. https:\/\/doi.org\/10.1016\/j.jaci.2017.01.009.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1602_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.alit.2021.10.004","volume":"71","author":"C Nakashima","year":"2022","unstructured":"Nakashima C, Yanagihara S, Otsuka A. Innovation in the treatment of atopic dermatitis: emerging topical and oral Janus kinase inhibitors. Allergol Int. 2022;71(1):40\u20136. https:\/\/doi.org\/10.1016\/j.alit.2021.10.004.","journal-title":"Allergol Int"},{"issue":"5","key":"1602_CR6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","volume":"13","author":"NA Gandhi","year":"2017","unstructured":"Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4\/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425\u201337. https:\/\/doi.org\/10.1080\/1744666X.2017.1298443.","journal-title":"Expert Rev Clin Immunol"},{"issue":"10086","key":"1602_CR7","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287\u2013303. https:\/\/doi.org\/10.1016\/S0140-6736(17)31191-1.","journal-title":"Lancet"},{"issue":"24","key":"1602_CR8","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348.","journal-title":"N Engl J Med"},{"key":"1602_CR9","unstructured":"Regeneron and Sanofi. Dupixent\u00ae (dupilumab). Full Prescribing Information; 2022."},{"issue":"15","key":"1602_CR10","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quint\u00e1s-Cardama","year":"2010","unstructured":"Quint\u00e1s-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109\u201317.","journal-title":"Blood"},{"issue":"4","key":"1602_CR11","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","volume":"85","author":"K Papp","year":"2021","unstructured":"Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Leung DYM, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021;85(4):863\u201372. https:\/\/doi.org\/10.1016\/j.jaad.2021.04.085.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1602_CR12","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jaad.2022.09.060","volume":"88","author":"K Papp","year":"2023","unstructured":"Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Forman SB, et al. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase 3 studies. J Am Acad Dermatol. 2023;88(5):1008\u201316. https:\/\/doi.org\/10.1016\/j.jaad.2022.09.060.","journal-title":"J Am Acad Dermatol"},{"key":"1602_CR13","unstructured":"Incyte Corporation. Opzelura\u00ae (ruxolitinib cream). Full Prescribing Information; 2025."},{"issue":"8","key":"1602_CR14","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1007\/s13555-024-01219-8","volume":"14","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, Kircik L, Blauvelt A, et al. Ruxolitinib cream in adolescents\/adults with atopic dermatitis meeting severity thresholds for systemic therapy: exploratory analysis of pooled results from two phase 3 studies. Dermatol Ther (Heidelb). 2024;14(8):2139\u201351.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1602_CR15","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2215356","volume":"34","author":"K Myers","year":"2023","unstructured":"Myers K, Silverberg JI, Parasuraman S, Pierce A, Eichenfield LF, Poulos C. Treatment preferences among patients with mild-to-moderate atopic dermatitis. J Dermatol Treat. 2023;34(1):2215356. https:\/\/doi.org\/10.1080\/09546634.2023.2215356.","journal-title":"J Dermatol Treat"},{"issue":"1_suppl","key":"1602_CR16","doi-asserted-by":"publisher","first-page":"10S","DOI":"10.1177\/1203475418803628","volume":"22","author":"MJ Gooderham","year":"2018","unstructured":"Gooderham MJ, Bissonnette R, Grewal P, Lansang P, Papp KA, Hong CH. Approach to the assessment and management of adult patients with atopic dermatitis: a consensus document. Section II: tools for assessing the severity of atopic dermatitis. J Cutan Med Surg. 2018;22(1_suppl):10S-S16.","journal-title":"J Cutan Med Surg"},{"issue":"8","key":"1602_CR17","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1001\/archderm.1992.01680180125022","volume":"128","author":"CC Long","year":"1992","unstructured":"Long CC, Finlay AY, Averill RW. The rule of hand: 4 hand areas = 2 FTU = 1 g. Arch Dermatol. 1992;128(8):1129\u201330.","journal-title":"Arch Dermatol"},{"key":"1602_CR18","first-page":"1","volume":"36","author":"CD Fryar","year":"2021","unstructured":"Fryar CD, Carroll MD, Gu Q, Afful J, Ogden CL. Anthropometric reference data for children and adults: United States, 2015-2018. Vital Health Stat 3. 2021;36:1\u201344.","journal-title":"Vital Health Stat 3"},{"key":"1602_CR19","unstructured":"IBM Corporation. IBM Micromedex RED BOOK. [cited 2024 July 18]. Available from: https:\/\/www.micromedexsolutions.com."},{"issue":"3","key":"1602_CR20","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","volume":"145","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Thaci D, Pangan AL, Hong HC, Papp KA, Reich K, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145(3):877\u201384. https:\/\/doi.org\/10.1016\/j.jaci.2019.11.025.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1602_CR21","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.19574","volume":"184","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437\u201349.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1602_CR22","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","volume":"156","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Blauvelt A, Eichenfield LF, et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. JAMA Dermatol. 2020;156(4):411\u201320.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"1602_CR23","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"384","author":"T Bieber","year":"2021","unstructured":"Bieber T, Simpson EL, Silverberg JI, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101\u201312.","journal-title":"N Engl J Med"},{"key":"1602_CR24","unstructured":"Lofland J, Naim A. Examining number needed to treat analyses among various prescription medications for treatment of atopic dermatitis. Academy of Managed Care Pharmacy; March 21\u201324, 2023; San Antonio, TX."},{"issue":"11","key":"1602_CR25","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1007\/s13555-025-01503-1","volume":"15","author":"MJ Gooderham","year":"2025","unstructured":"Gooderham MJ, Hong HC-H, Wang D, et al. Network meta-analysis of 1.5% ruxolitinib cream versus systemic agents in the treatment of moderate atopic dermatitis. Dermatol Ther (Heidelb). 2025;15(11):3313\u20133328.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1602_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2147\/CEOR.S506043","volume":"17","author":"J Liu","year":"2025","unstructured":"Liu J, Desai K, Teng CC, Sturm D, Stockbower G, Patadia H, et al. Atopic dermatitis treatments before and after initiation of ruxolitinib cream: 6-month follow-up analysis of a US payer claims database. Clinicoecon Outcomes Res. 2025;17:69\u201377. https:\/\/doi.org\/10.2147\/CEOR.S506043.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"4","key":"1602_CR27","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jaad.2017.06.042","volume":"77","author":"EL Simpson","year":"2017","unstructured":"Simpson EL, Bruin-Weller M, Flohr C, Ardern-Jones MR, Barbarot S, Deleuran M, et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol. 2017;77(4):623\u201333. https:\/\/doi.org\/10.1016\/j.jaad.2017.06.042.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1602_CR28","doi-asserted-by":"publisher","DOI":"10.25251\/skin.8.supp.374","volume":"8","author":"J Silverberg","year":"2024","unstructured":"Silverberg J, Augustin M, Eichenfield L, Lio P, Guttman-Yassky E, Reck Atwater A, et al. A checklist to aid in identifying patients with atopic dermatitis who are candidates for systemic therapy. SKIN J Cutan Med. 2024;8(2):s374. https:\/\/doi.org\/10.25251\/skin.8.supp.374.","journal-title":"SKIN J Cutan Med"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01602-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01602-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01602-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:40:23Z","timestamp":1770190823000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01602-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1602"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01602-z","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Omar Noor has served as a speaker for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Castle Biosciences, Dermavant, EPI Health, Galderma, Incyte Corporation, Journey Medical, Lilly USA, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB; as a consultant for AbbVie, Arcutis, Bristol Myers Squibb, Castle Biosciences, Dermavant, Galderma, Incyte Corporation, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, and UCB; as a principal investigator for AbbVie and Proctor & Gamble; and as a national trainer for Galderma. Jinan Liu, Daniel Sturm, Haobo Ren, and Dilan Paranagama are employees and shareholders of Incyte Corporation. Zelma C. Chiesa Fuxench has received research grants from Brexogen, Lilly, LEO Pharma, Regeneron, Sanofi, Tioga, and Vanda for work related to atopic dermatitis and from Menlo Therapeutics and Galderma for work related to prurigo nodularis; has served as a consultant for AbbVie, Asthma and Allergy Foundation of America, Incyte Corporation, National Eczema Association, and Pfizer; and has received honoraria for continuing medical education sponsored by education grants from Regeneron\/Sanofi and Pfizer for work in atopic dermatitis and from Beirsdorf for work related to skin cancer and sun protection. Raj Chovatiya has served as an advisor, consultant, speaker, and\/or investigator for AbbVie, Acelyrin, Alumis, Amgen, AnaptysBio, Apogee, Arcutis, Argenx, Astria, Avalere Health, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celldex, CLn Skin Care, Dermavant, Eli Lilly and Company, EMD Serono, Formation Bio, Galderma, Genentech, GlaxoSmithKline, Incyte Corporation, Johnson & Johnson, Kenvue, LEO Pharma, L\u2019Or\u00e9al, Nektar Therapeutics, Novartis, Opsidio, Pfizer, RAPT, Regeneron, Sanofi, Sitryx, Takeda, TRex Bio, UCB, and Zai Lab and is an Editorial Board member of\n                      Dermatology and Therapy\n                      but was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This analysis utilized patient data from previously conducted studies. No new studies with human participants or animals were performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}